Basic Study
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Surg. Jul 27, 2024; 16(7): 2296-2307
Published online Jul 27, 2024. doi: 10.4240/wjgs.v16.i7.2296
Yangyin Huowei mixture alleviates chronic atrophic gastritis by inhibiting the IL-10/JAK1/STAT3 pathway
Shan-Shan Xie, Yong Zhi, Chang-Ming Shao, Bin-Fang Zeng
Shan-Shan Xie, Yong Zhi, Chang-Ming Shao, Bin-Fang Zeng, Department of Traditional Chinese Medicine, Xinjiang Medical University, Urumqi 830017, Xinjiang Uygur Autonomous Region, China
Author contributions: Xie SS, Zhi Y, Shao CM, and Zeng BF designed the research; Shao CM, Zeng BF, and Xie SS contributed new reagents/analytic tools; Xie SS and Zeng BF analyzed the data; Xie SS wrote the paper; all authors were involved in the critical review of the results and have contributed to, read, and approved the final manuscript.
Supported by the Project of Regional Collaborative Innovation of Xinjiang Uygur Autonomous Region, No. 2022E01008; and the Graduate Innovation Project of Xinjiang Medical University, No. CXCY2023012.
Institutional review board statement: This study protocol was approved by Xinjiang Medical University.
Institutional animal care and use committee statement: All procedures involving animals were reviewed and approved by the Institutional Animal Care and Use Committee of the Xinjiang Medical University (IACUC protocol number: IACUC-20210315-04).
Conflict-of-interest statement: The authors declare no conflict of interest for this paper.
Data sharing statement: Data generated from this investigation are available upon reasonable quest from the corresponding author.
ARRIVE guidelines statement: The authors have read the ARRIVE guidelines, and the manuscript was prepared and revised according to the ARRIVE guidelines.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Bin-Fang Zeng, PhD, Professor, Department of Traditional Chinese Medicine, Xinjiang Medical University, No. 567 Shangde North Road, Shuimogou District, Urumqi 830017, Xinjiang Uygur Autonomous Region, China. xjmuzbf@126.com
Received: March 14, 2024
Revised: May 9, 2024
Accepted: June 4, 2024
Published online: July 27, 2024
Processing time: 129 Days and 21.7 Hours
Abstract
BACKGROUND

The Chinese medicine Yangyin Huowei mixture (YYHWM) exhibits good clinical efficacy in the treatment of chronic atrophic gastritis (CAG), but the mechanisms underlying its activity remain unclear.

AIM

To investigate the therapeutic effects of YYHWM and its underlying mechanisms in a CAG rat model.

METHODS

Sprague-Dawley rats were allocated into control, model, vitacoenzyme, and low, medium, and high-dose YYHWM groups. CAG was induced in rats using N-methyl-N′-nitro-N-nitrosoguanidine, ranitidine hydrochloride, hunger and satiety perturbation, and ethanol gavage. Following an 8-wk intervention period, stomach samples were taken, stained, and examined for histopathological changes. ELISA was utilized to quantify serum levels of PG-I, PG-II, G-17, IL-1β, IL-6, and TNF-α. Western blot analysis was performed to evaluate protein expression of IL-10, JAK1, and STAT3.

RESULTS

The model group showed gastric mucosal layer disruption and inflammatory cell infiltration. Compared with the blank control group, serum levels of PGI, PGII, and G-17 in the model group were significantly reduced (82.41 ± 3.53 vs 38.52 ± 1.71, 23.06 ± 0.96 vs 11.06 ± 0.70, and 493.09 ± 12.17 vs 225.52 ± 17.44, P < 0.01 for all), whereas those of IL-1β, IL-6, and TNF-α were significantly increased (30.15 ± 3.07 vs 80.98 ± 4.47, 69.05 ± 12.72 vs 110.85 ± 6.68, and 209.24 ± 11.62 vs 313.37 ± 36.77, P < 0.01 for all), and the protein levels of IL-10, JAK1, and STAT3 were higher in gastric mucosal tissues (0.47 ± 0.10 vs 1.11 ± 0.09, 0.49 ± 0.05 vs 0.99 ± 0.07, and 0.24 ± 0.05 vs 1.04 ± 0.14, P < 0.01 for all). Compared with the model group, high-dose YYHWM treatment significantly improved the gastric mucosal tissue damage, increased the levels of PGI, PGII, and G-17 (38.52 ± 1.71 vs 50.41 ± 3.53, 11.06 ± 0.70 vs 15.33 ± 1.24, and 225.52 ± 17.44 vs 329.22 ± 29.11, P < 0.01 for all), decreased the levels of IL-1β, IL-6, and TNF-α (80.98 ± 4.47 vs 61.56 ± 4.02, 110.85 ± 6.68 vs 89.20 ± 8.48, and 313.37 ± 36.77 vs 267.30 ± 9.31, P < 0.01 for all), and evidently decreased the protein levels of IL-10 and STAT3 in gastric mucosal tissues (1.11 ± 0.09 vs 0.19 ± 0.07 and 1.04 ± 0.14 vs 0.55 ± 0.09, P < 0.01 for both).

CONCLUSION

YYHWM reduces the release of inflammatory factors by inhibiting the IL-10/JAK1/STAT3 pathway, alleviating gastric mucosal damage, and enhancing gastric secretory function, thereby ameliorating CAG development and cancer transformation.

Keywords: Yangyin Huowei mixture; IL-10/JAK1/STAT3 pathway; Chronic atrophic gastritis; Inflammatory factor; Gastric secretory function

Core Tip: This study aimed to investigate the therapeutic effects of Yangyin Huowei mixture (YYHWM) on chronic atrophic gastritis (CAG) and its potential mechanism. A CAG model was induced through the administration of a composite factor. The study observed the pathological damage to the stomach tissue, gastric secretory function, inflammatory factors, and protein expression levels of the IL-10/JAK1/STAT3 pathway. Ultimately, it was discovered that YYHWM can improve the pathological damage to the stomach tissue and enhance the gastric secretory function of CAG rats, which may be attributed to its suppression of the IL-10/JAK1/STAT3 pathway and reduction of inflammatory factor levels.